Introduction
============

The prevalence of insomnia in Asian and Western countries ranges from 5% to 40% [@B1]-[@B7]. It has been found to correlate with a number of psychological diseases such as depression [@B5] and physical illnesses such as diabetes [@B8], hypertension, and cardiovascular disease [@B9]-[@B12]. Thus, insomnia is a major public health concern with considerable personal and socioeconomic burdens [@B13]. Typical treatments for patients with insomnia include psychological therapy and the use of medications [@B14]. The two most commonly prescribed medications to treat insomnia are benzodiazepines (BZDs) and non-benzodiazepines (non-BZDs), and other drugs such as gamma-aminobutyric acid agonists, melatonin receptor agonists, sedating antidepressants, antihistamines, and eugeroic drugs are also used but less frequently [@B15]. Sedative-hypnotics are also prescribed to patients with diseases such as generalized anxiety disorder, addiction, agitation, neurological disorders, muscle spasticity, involuntary movement disorder, alcohol withdrawal, and anxiety associated with cardiovascular or gastrointestinal conditions [@B16]. However, associations between the usage of sedative-hypnotics and potential side effects, such as cancer and death, have not yet been clearly established.

Concerns about the possible side effects of sedative-hypnotics in humans have existed since the Cancer Prevention Study I of the American Cancer Society first documented that the consumption of hypnotics was associated with excessive deaths in 1979 [@B17], [@B18]. Although a few population-based studies have investigated the correlation between the use of sedative-hypnotics and corresponding mortality [@B19]-[@B31], no consistent relationships have been established. Few local studies have attempted to determine the correlations between the use of sedative-hypnotics and potential carcinogenicity in the Taiwanese population, but the influence of both insomnia and the use of sedative-hypnotics has not been explored [@B32]-[@B35]. Moreover, most studies have analyzed either the use of BZDs [@B33], [@B34] or non-BZDs [@B32] alone, and thus the overall influence of how the use of sedative-hypnotics, including both BZDs and non-BZDs, correlates with carcinogenicity in the general Taiwanese population remains to be elucidated. To our knowledge, our study is the first to specifically investigate the correlations between subsequent cancer development, the use of sedative-hypnotics, and insomnia in the Taiwanese population.

Materials and Methods
=====================

Data Sources
------------

The National Health Insurance (NHI) Project was initiated and maintained by the Health and Welfare Data Science Center of the Ministry of Health and Welfare. It captures all the reimbursable items of consolidated health insurance claims from every single payer. The NHI program has covered more than 96% of the Taiwanese population and it has already established contact with 97% of the local clinics and hospitals since the end of 1996 [@B34]. The full population file from the NHI database was used to analyze the risk of subsequent cancer in a more accurate manner. Information from each of the medical claims records included 1) the patient\'s demographic details, 2) clinical details concerning diseases (according to the International Classification of Diseases, Ninth Revision, Clinical Modification; ICD-9-CM), and 3) details of health care service such as drug prescription and cost. This study was reviewed and approved by the Joint Institutional Review Board of Taipei Medical University (N201611010).

Study samples
-------------

This study examined the risk of cancer in three sedative-hypnotics-exposed groups and one sedative-hypnotics-unexposed group. Patients who had been diagnosed with insomnia (ICD-9-CM Codes 307.40-307.42, 307.44, 307.49, or 780.52) and prescribed sedative-hypnotic medications were classified as the first exposure group (Inso-Hyp group). The date each patient was first diagnosed with insomnia was within January 1, 2002 and December 31, 2004. To avoid coding errors, only patients with at least two diagnosis records for insomnia within the same year were recruited. The index date was defined as the first outpatient visit for insomnia treatment. Prescription of sedative-hypnotic drugs was defined as at least 30 defined daily dose (DDD) per year [@B36] until the first diagnosis of cancer, death, or endpoint of the follow-up period. Patients with any two consecutive prescription intervals greater than three months were classified as having discontinued the prescription and were excluded [@B37]. In the second exposed group, all patients were diagnosed with insomnia but were not prescribed any sedative-hypnotics during the entire follow-up period (Inso-NonHyp). The third exposed group consisted of patients who had received a sedative-hypnotics prescription for any reason other than insomnia (NonInso-Hyp). The definition of insomnia for the Inso-NonHyp and NonInso-Hyp was same as for the Inso-Hyp group. Any patients in these three exposure groups were excluded if they had either been diagnosed with insomnia or prescribed a sedative-hypnotics drug between 2000 and 2001. The remaining beneficiaries without diagnosis of insomnia or sedative-hypnotic prescription between 2000 and 2013 were recruited into the unexposed group (NonInso-NonHyp), and the first record of medical service use was defined as their index visit. Common exclusion criteria for all four groups included any patients who had (1) a previous diagnosis of cancer between 2000 and 2001 or (2) a previous diagnosis of cancer before the index date, (3) who were aged under 18 years on the index date, or (4) who had a latency period less than two years. Patients for inclusion in the NonInso-NonHyp group were selected by matching to those in the NonInso-Hyp group according to age, sex, index year, and Charlson comorbidity score (CCI; four for each patient). Patients for the Inso-NonHyp group were selected to match with those in the Inso-Hyp group according to same way. Finally, 43,585 patients were included in this retrospective study.

Variables of Interest
---------------------

The risk of subsequent cancer incidence in each cohort (codes according to the International Classification of Diseases for Oncology, third edition, in the Cancer Registry file) was evaluated. From the respective index dates to the day with first diagnosis of cancer, date of death, or the end of the follow-up period on December 31, 2015, the patients were individually followed for 2 to 14 years. We retrospectively investigated the risk of nine major cancer types in Taiwan, namely oral cancer (C00-C06, C09-C10, C12-C14), stomach cancer (C16), colon cancer (C18-C21), liver cancer (C22), lung cancer (C33-C34), skin cancer (C44), breast cancer (C50), corpus cancer (C54), and prostate cancer (C61) [@B38]. Only female subjects were included in the analysis of the associated risk of subsequent breast cancer.

Sedative-hypnotics were classified as either BZDs or non-BZDs. Alprazolam, bromazepam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, estazolam, fludiazepam, flunitrazepam, flurazepam, lorazepam, medazepam, midazolam, nitrazepam, nordazepam, oxazepam, and triazolam were classified as BZDs, and zolpidem, zopiclone, and zaleplon were classified as non-BZDs [@B39]. Patients who received a prescription for both BZDs and non-BZDs during the study period were excluded from the drug type analysis. Three groups of different half-life duration of sedative-hypnotic drugs were further analyzed. We defined a drug as short acting, intermediate acting, or long acting if it had a half-life of less than 10 hours, 10 to 35 hours, or more than 35 hours, respectively [@B40]. Moreover, patients who had ever switched from using a long-acting drug to a short-acting drug were sorted into the long-acting group. Low-dose users were patients with a prescribed yearly mean DDD of 7 to 30 during the follow-up period, medium-dose users were those with a prescribed yearly mean DDD of 31 to 90, and high-dose users were patients with a prescribed yearly mean DDD of ≥ 91 [@B36].

Statistical Analysis
--------------------

Demographic information for each patient was obtained from the Registry for Beneficiaries file. There were four groups for patient\'s age: younger than 30 years old, 30-44 years old, 45-64 years old, and 65 years or older. Patients were divided into three groups according to their average monthly income: \< US\$640 (New Taiwan Dollars \[NT\$\]20,000), US\$640-\$1,280 (NT\$20,000-39,999), and ≥ US\$1,281 (≥ NT\$40,000). Northern, Central, Southern, and Eastern administrative regions of Taiwan were used as criteria for classifying residential area. The urbanization level of patient\'s residence was defined as urban, suburban, or rural. CCI score was used to evaluate any preexisting comorbidities [@B41]. Patients were subsequently stratified into three groups according to the sum of points (range: 0 to 6): 0, 1, ≥ 2 points [@B42]. The chi-squared test was used to analyze differences in the demographic information of four patient groups. The incidence density rate of each at-risk population was defined as the number of incident cases divided by the sum of the person-years. The crude hazard ratios (CHRs) for developing cancer were estimated using univariate Cox proportional hazards model. The adjusted hazard ratio (AHR) represented the differing risks for the study groups after controlling for demographic information of patient. The between-group differences in the survival rates and curves of survival distributions for developing cancer were assessed by Kaplan-Meier method and log-rank test. SAS statistical package (SAS systems for Windows, Version 9.2; Cary, NC, USA) was used for all statistical analyses. The statistically significant *p* value was set at \< 0.05.

Results
=======

The cohort of this study consisted of a total of 43,585 patients from Taiwan\'s National Health Insurance Research Database (NHIRD); 4,266 patients were assigned to the Inso-Hyp group, 17,064 patients were sorted into the Inso-NonHyp group, 4,451 patients comprised the NonInso-Hyp group, and 17,804 patients constituted the Noninso-NonHyp group (Table [1](#T1){ref-type="table"}). Significant differences were identified in the demographic characteristics of the patients in these four groups. In general, most of the subjects had a monthly income under \$640 (66.4%-78.8%) and lived in the Northern (48.6%-57.3%) and urban region (56.9%-57.7%). Compared with patients without insomnia, more patients in the Inso-Hyp and Inso-NonHyp groups were younger than 30 (4.4% and 4.6%, respectively) or were female (48.1%). In addition, patients who had not been prescribed any sedative-hypnotics exhibited significantly lower CCIs than those who had.

Table [2](#T2){ref-type="table"} displays the CHRs of subsequent cancer incidence in our study cohort. The patients with exposure to sedative-hypnotic prescriptions exhibited higher hazard ratios for cancer compared with those without sedative-hypnotic prescriptions: The CHR was 1.47 (CI: 1.21-1.79) for the Inso-Hyp group compared with the Inso-NonHyp group and 1.65 (CI: 1.36-2.01) for the NonInso-Hyp group compared with the NonInso-NonHyp group. In addition, patients aged 45 years or older were associated with higher densities of cancer incidence than those who were younger than 30 years old. The densities of cancer incidence were significantly higher in male patients (CHR: 1.55, 95% confidence interval (CI): 1.37-1.76), patients with a monthly income \< \$640 (CHR: 1.34, 95% CI: 1.07-1.67), or who lived in the Southern region of Taiwan. Subjects with a CCI score equal to or greater than 1 were also more likely to subsequently develop cancer when compared with patients whose CCI score was zero.

As Table [3](#T3){ref-type="table"} presents, for patients receiving a diagnosis of insomnia, those prescribed long-acting sedative-hypnotic drugs exhibited a higher risk of developing cancer (AHR: 1.73, CI: 1.37-2.19) than those without sedative-hypnotic prescriptions. Patients having a prescribed mean DDD of at least 7 per year exhibited a higher risk of cancer than those without any sedative-hypnotic prescriptions. In particular, patients with a low dosage (AHR: 2.70, 95% CI: 1.12-6.54) had a 2.7-fold increased risk of a subsequent cancer incidence. Noninsomniac patients with a prescription of BZD had a higher risk of cancer compared with those without sedative-hypnotic drugs (AHR: 1.51, CI: 1.17-1.95). With respect to the half-life of the prescribed sedative-hypnotics, it was found that the risk of subsequently developing cancer among the patients with either short-, intermediate-, or long-acting drugs was comparable (AHR: 1.75, 95% CI: 1.09-2.82; AHR: 1.65, 95% CI: 1.21-2.26; and AHR: 1.69, 95% CI: 1.31-2.17, respectively). Patients having a prescribed mean DDD of at least 7 per year exhibited a higher risk of cancer than those without any sedative-hypnotic prescription, especially for those receiving a low dosage (AHR: 5.47, CI: 4.10-7.30).

The incidence densities of each type of cancer for each of the four groups within the follow-up period are summarized in Table [4](#T4){ref-type="table"}. In general, after adjustment for individual age, sex, income, residential region, urbanization, and CCI scores, patients who received sedative-hypnotic prescriptions exhibited higher hazard ratios for cancer compared with those without sedative-hypnotic prescriptions: AHR 1.49 (CI: 1.22-1.82) in Inso-Hyp group compared with the Inso-NonHyp group and 1.68 (CI: 1.38-2.05) in the NonInso-Hyp group compared with NonInso-NonHyp group (Table [4](#T4){ref-type="table"}). In particular, the Inso-Hyp group exhibited a higher probability of developing oral and breast cancer than the Inso-NonHyp group did, and the NonInso-Hyp group exhibited a significantly higher risk of developing liver and breast cancers than the NonInso-NonHyp group did.

Using the Kaplan-Meier method, the overall 14-year cancer-free survival curves for the four groups were calculated and are presented in Figure [1](#F1){ref-type="fig"}. Log-rank testing revealed that there were significantly lower cancer-free survival rates for Inso-Hyp and NonInso-Hyp groups than those for Inso-NonHyp and NonInso-NonHyp groups (*p* \< 0.001).

Discussion
==========

In this 14-year cohort study, we historically and prospectively analyzed the relationship between sedative-hypnotics usage and subsequent cancer risk on the basis of 21,330 patients with insomnia and 22,255 patients without insomnia collected from the NHIRD in Taiwan. The findings of the present study provided evidence that the use of sedative-hypnotics in patients either with insomnia or without was associated with an increased risk of subsequent cancer development in the Taiwanese population. Thus, the use of sedative-hypnotics to treat patients with or without insomnia is discouraged. For patients who clinically require sedative-hypnotics, they should be advised and warned of the potential cancer risks before receiving a prescription.

The underlying mechanisms and reasons for the evident relationship between sedative-hypnotics and cancer incidence remain to be determined. A report has suggested that sedative-hypnotics usage leads to weakened immune function. For instance, some animal studies have discovered that BZDs such as diazepam and midazolam impaired the processes of spreading, phagocytosis, and oxidative bursting of macrophages [@B43], [@B44]. These impairments can be partially explained by the reduced release of the proinflammatory cytokines interleukin-6 and interleukin-13 in blood cells because of the activation of their BZD receptors [@B45]. Figure [2](#F2){ref-type="fig"} shows how BZDs may contribute to increased risk of subsequent cancer through the above mechanism.

Sedative-hypnotics are also prescribed to patients with various types of psychiatric illnesses [@B46]. For instance, BZDs are commonly prescribed to patients with bipolar disorder [@B46] or schizophrenia [@B47] in Taiwan, and non-BZD drugs are prescribed to patients with depression [@B48]; this could account for the sedative-hypnotics prescribed to patients without insomnia in our study cohort (Table [3](#T3){ref-type="table"}). Psychological parameters may alter immune function [@B49]. Moreover, individuals who regularly use sedative-hypnotics also tend to have more psychological problems. Indeed, one of our previous studies demonstrated that the use of sedative-hypnotics, including both BZDs and non-BZDs, increased the risk of developing various types of psychiatric disorders such as depressive disorder, bipolar disorder, and anxiety disorder [@B46]. Moreover, randomized controlled trials have demonstrated that the use of sedative-hypnotics increased the incidence of depression [@B50]. Non-BZDs such as zolpidem have been associated with a relatively high incidence of depression [@B50]. Taken together, these study findings suggest that the increased subsequent cancer risk can at least be partially accounted for by the weakened immune function that results from both intrinsic psychiatric weaknesses and extrinsic usage of sedative-hypnotics. Figure [3](#F3){ref-type="fig"} shows the relationships between psychological illnesses, sedative-hypnotics and the impaired immune function. It has been recently suggested that sedative-hypnotics are clastogens that can transform normal cells into cancer through disruption or breakages of chromosomes [@B51], [@B52]. The author pointed out that non-BZDs such as zopiclone, zaleplon and ramelteon, based on the findings from the Center for Drug Evaluation and Research, are clastogenic in cell models [@B51]. Although both zopiclone and zaleplon usage were included in the non-BZDs group in our study, there was no significant increase in the risk of having subsequent cancers in subjects either with insomnia or without insomnia (Table [3](#T3){ref-type="table"}). The conflict may be due to the fact that zolpidem was also included in the non-BZDs group in our analysis. Further in-vitro studies on the effect of non-BZDs in inducing cell transformation are warranted. Figure [4](#F4){ref-type="fig"} depicted one of the possible mechanisms how non-BZDs induce carcinogenesis.

The use of long-acting sedative-hypnotics, but not short- or intermediate-acting ones, increased the risk of subsequent cancer development among patients with insomnia in our study. This suggests that the sedative-hypnotics having a half-life longer than 35 hours should be restricted and not prescribed to patients with insomnia. A possible reason for this is that longer duration of sleep that results from the use of short- or intermediate-acting sedative-hypnotics may help restore their normal immune function, which could compensate for the risk of subsequent cancer. By contrast, the use of long-acting sedative-hypnotics by patients with insomnia results in more than half the dose consumed the previous night remaining in the patient\'s system until just before the next dose is consumed. Thus, the negative effect of this carry-over effect may significantly interrupt the circadian rhythm of these patients. Disruption of the normal circadian rhythm has been reported to increase the risk of developing cancer [@B53]. Furthermore, Thompson et al has recently proposed that disruption of the circadian rhythm and suppression of nocturnal production of melatonin, which has been shown to promote DNA repair in animal models [@B54]-[@B56], could be potential mechanisms that contribute to an increased risk of colorectal adenomas due to shorter sleep duration in a group of subjects who were having colonoscopy screening [@B57]. In contrast, no significant increase in the risk of colon cancer was observed in the Inso-NonHyp group when compared with the NonInso-NonHyp group. A possible reason to explain this is that the risk of colon/colorectal malignancy had been reduced because of the implementation of the Nationwide Colorectal Cancer Screening Program since 2004 in Taiwan [@B58]. Colon/colorectal malignancy can be prevented if early detection of precancerous stage and subsequent intervention can be achieved [@B59]. Thus, we suggest that more frequent cancer screening (e.g. for colon cancer) could be provided to individuals who are having sedative-hypnotics.

The use of sedative-hypnotics resulted in a 2.4-fold increase in the risk of oral cancer in patients with insomnia in our study, and a 2.5-fold risk of future liver cancer was evident in patients without insomnia who used sedative-hypnotics. As we discussed earlier, patients who use sedative-hypnotics are more likely to have weakened immune function; thus, they are more susceptible to various types of viral attack. The viral infection hypothesis has been suggested to explain the high risk of oral and liver cancers that is associated with sedative-hypnotics usage [@B60]-[@B62]. For example, human papillomavirus (HPV) has been determined to contribute to the development of oral cancer [@B63], and hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account for the majority of primary liver cancer cases in Taiwan [@B64].

Experimental studies have suggested that diazepam, one of the BZDs family members, may promote breast cancer growth [@B65], [@B66]. However, this hypothesis was rejected by Kleinerman et al., who concluded that the breast cancer growth was not associated with the use of diazepam [@B67]. In addition, two other groups of researchers also failed to discern a significant association between the use of sedative-hypnotics and breast cancer risk [@B68], [@B69]. Pottegard et al. concluded that the odds ratio for breast cancer among patients in their Danish cohort comprised of approximately 1.3 million individuals who used BZDs or BZD-related drugs was close to unity (AHR: 1.01, 95% CI 0.90-1.14) [@B70]. In Halapy\'s study, BZDs usage did not correlate with an increased breast cancer rate in their Canadian cohort [@B68]. However, we discovered that female patients in our study who used sedative-hypnotics had at least a 2.2-fold increased risk of developing subsequent breast cancer (Table [4](#T4){ref-type="table"}). This finding is partially supported by Kao et al., who determined that the use of Zolpidem, the most commonly used non-BZDs drug, was associated with a 1.84-fold increase in breast cancer risk in Taiwanese women [@B32]. Further investigation into this area should be undertaken in the future. Different mechanisms of breast carcinogenesis may vary among patients of different ethnicities, which could account for the discrepant research findings.

Pottegard et al have recently concluded that the long term usage of either BZDs and BZD-related drugs did not significantly increase the overall risk of subsequent cancer [@B71]. However, significant increases (at least 1.35 folds) in the risks of site-specific cancers such as cancers of esophagus, stomach, liver, pancreas, lung, bronchus and pleura and melanoma of skin could still be demonstrated. In particular, a 1.8 folds increase in the risk of having liver cancer for patients taking sedative-hypnotics was observed. Although the author suggested that heavy alcohol usage could be a confounding factor which contributed to the increased risk [@B71], BZDs such as diazepam and oxazepam were CYP4A inducers in mice that could account for their ability to promote tumorigenesis in liver [@B72]. Furthermore, liver is the organ responsible for drug metabolism. Thus, the potential side effect of prolonged use of sedative-hypnotics on liver may be similar to that of the prolonged use of acetaminophen, which was associated with slightly increased risk of liver cancer [@B73], possibly due to liver glutathione depletion, increased oxidative stress, mitochondrial dysfunction [@B74]. Taking these together, it is possible that the ability of sedative-hypnotics to initiate/promote tumor growth may be different on different organs and it may exert a more direct and stronger carcinogenic effect on liver. Mechanistic study of hepatocarcinogenic effect exerted by sedative-hypnotics is warranted.

Compared with a recent Taiwanese study, Lan et al have shown that the use of Zolpidem was also associated with increased cancer risk [@B35]. Since this study targeted at investigating the relationships between the use of BZDs and non-BZDs and various mortality, no further information was provided on the potential risk of subsequent cancer after prolonged usage of BZDs and non-BZDs in the general Taiwanese population. Thus, our study provided the most recent findings to indicate that the overall cancer risk was increased with prolonged usage of sedative-hypnotics in Taiwanese population (Table [4](#T4){ref-type="table"}). Although prescription of sedative-hypnotics is still the main treatment regimen for patients with insomnia [@B14], cognitive behavior therapy (CBT) appears to be an alternative treatment option [@B75]. In consideration of the time and costs associated with the conventional face-to-face treatment session, a randomized controlled trial has suggested that video-based CBT (V-CBT) can also produces significant and sustainable treatment effects in a group of breast cancer patients with insomnia symptoms [@B76]. Therefore, the feasibility of the use of V-CBT to substitute sedative-hypnotics medication should be investigated.

This study has a few strengths. To the best of our knowledge, it is the first study to investigate the correlations between sedative-hypnotics usage (including both BZDs and non-BZDs) and subsequent cancer risk in patients with or without insomnia in the Taiwanese population. Moreover, the cohort in this study was derived from the NHIRD, which has a national coverage rate of approximately 96%, and thus this study is representative of the total population in Taiwan. The data included in this study encompass a period of 14 years (2002-2015), which is relatively longer than other local researches that have been conducted; thus, any potential bias could be minimized. In addition, patients enrolled in this study were carefully matched in terms of age, sex, index year, and CCI score. Last, only patients who received a cumulative DDD prescription of more than 30 per year were included for most of the statistical analyses with the exception of dosage analysis. This was done to eliminate the effect of sedative-hypnotics usage that was unlikely to have a significant effect on the development of subsequent cancers. Several limitations have also been identified. First, data from the NHIRD do not include factors that are potentially related to sedative-hypnotics usage and cancer risk such as drinking habit, smoking habit, exercise habit, and family history of cancer [@B77]. These are major risk factors for multiple cancers and thus these may have constituted residual confounding effects in this study. Second, the use of sedative-hypnotics in the claims data was inferred from prescription data. Thus, it might not accurately represent the actual usage among patients. The cancer risk associated with the potential use of sedative-hypnotics could have been underestimated. However, the correlated cancer risk could also have been overestimated if some patients had obtained sedative-hypnotics from sources other than NHI, but this situation was unlikely because all sedative-hypnotics require a prescription in Taiwan. Third, a causal relationship could not be established because observational data was used in this study. Last, main findings from this current study have not been validated in another independent cohort due to limited number of subjects currently available.

Conclusions
===========

This study presented evidence that the use of sedative-hypnotics in patients either with or without insomnia was associated with subsequent cancer development in the Taiwanese population. The use of long-acting and high dose of sedative-hypnotics increased the risk of subsequent cancer development. The use of sedative-hypnotics resulted in increased risks of oral, liver, and breast cancer in patients. The increased risk of cancer should be explained to patients who require sedative-hypnotics before a prescription is given. The use of sedative-hypnotics is discouraged in the long term, and other treatments, such as cognitive behavior therapy, should be considered to substitute the prescription of sedative-hypnotics in Taiwan. Cancer screening can also be provided to individuals who are receiving sedative-hypnotics in a more frequent manner.
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![A diagram showing a potential mechanism how BZDs, such as diazepam or midazolam, contribute to the increased risk of subsequent cancers, such as oral and liver cancers, in this study. The numbers refer to the corresponding supporting references.](jcav10p2288g002){#F2}

![A diagram showing the relationships between psychological illnesses, sedative-hypnotics and impaired immune function.](jcav10p2288g003){#F3}

![A diagram showing a potential mechanism how non-BZDs such as zopiclone or zaleplon contribute to increased risk of subsequent cancers. The number refers to the corresponding supporting reference.](jcav10p2288g004){#F4}

###### 

Demographic characteristics of patients in the Inso-Hyp, Inso-NonHyp, NonInso-Hyp, and NonInso-NonHyp groups

  Variable                       Inso-Hyp (N = 4,266)   Inso-NonHyp (N = 17,064)   NonInso-Hyp (N = 4,451)   NonInso-NonHyp (N = 17,804)                                
  ------------------------------ ---------------------- -------------------------- ------------------------- ----------------------------- ------ ------ ------- ------ ---------
  Age (y)                                                                                                                                                               \<0.001
  Younger than 30                188                    4.4                        789                       4.6                           102    2.3    411     2.3    
  30-44                          1464                   34.3                       5813                      34.1                          1078   24.2   4306    24.2   
  45-64                          1987                   46.6                       7957                      46.6                          2258   50.7   9036    50.8   
  65 or older                    627                    14.7                       2505                      14.7                          1013   22.8   4051    22.8   
  Sex                                                                                                                                                                   \<0.001
  Female                         2051                   48.1                       8204                      48.1                          1816   40.8   7264    40.8   
  Male                           2215                   51.9                       8860                      51.9                          2635   59.2   10540   59.2   
  Income (US\$)                                                                                                                                                         \<0.001
  ≥1281 (≥NT\$40000)             362                    8.5                        2029                      11.9                          408    9.2    1259    7.1    
  640-1280 (NT\$20000-\$39999)   699                    16.4                       3706                      21.7                          707    15.9   2516    14.1   
  \<640 (\<NT\$20000)            3205                   75.1                       11329                     66.4                          3336   75.0   14029   78.8   
  Region                                                                                                                                                                \<0.001
  Northern                       2074                   48.6                       8865                      52.0                          2212   49.7   10193   57.3   
  Central                        946                    22.2                       3600                      21.1                          876    19.7   3003    16.9   
  Southern                       1171                   27.5                       4265                      25.0                          1277   28.7   4185    23.5   
  Eastern                        75                     1.8                        334                       2.0                           86     2.0    423     2.4    
  Urbanization                                                                                                                                                          \<0.001
  Urban                          2426                   56.9                       9832                      57.6                          2558   57.5   10272   57.7   
  Suburban                       1450                   34.0                       5589                      32.8                          1460   32.8   5517    31.0   
  Rural                          390                    9.1                        1643                      9.6                           433    9.7    2015    11.3   
  CCI                                                                                                                                                                   \<0.001
  0                              1701                   39.9                       7760                      45.5                          1565   35.2   7932    44.6   
  1                              1124                   26.4                       4479                      26.3                          1123   25.2   3548    19.9   
  ≥2                             1441                   33.8                       4825                      28.3                          1763   39.6   6324    35.5   

CCI, Charlson comorbidity index; Inso-Hyp, patients with insomnia and sedative-hypnotic prescriptions; Inso-NonHyp, patients with insomnia and without sedative-hypnotic prescriptions; NonInso-Hyp, patients with sedative-hypnotics and without insomnia; NonInso-NonHyp, patients with neither insomnia nor sedative-hypnotic prescriptions.

###### 

Crude hazard ratios for cancer in patients in the Inso-Hyp, Inso-NonHyp, NonInso-Hyp, and NonInso-NonHyp groups

  Variable                       Cancer                      
  ------------------------------ -------- ----------- ------ ------------------------
  Age (y)                                                    
  Younger than 30                7        10782.79    0.65   1.00
  30-44                          100      83935.98    1.19   1.88 (0.88-4.05)
  45-64                          494      137295.32   3.60   5.75 (2.73-12.12)\*\*
  65 or older                    469      53457.42    8.77   14.00 (6.64-29.52)\*\*
  Sex                                                        
  Female                         368      127644.11   2.88   1.00
  Male                           702      157827.40   4.45   1.55 (1.37-1.76)\*\*
  Income (US\$)                                              
  ≥1281 (≥NT\$40000)             84       27310.87    3.08   1.00
  640-1280 (NT\$20000-\$39999)   144      50524.91    2.85   0.93 (0.71-1.22)
  \<640 (\<NT\$20000)            842      207635.73   4.06   1.34 (1.07-1.67)\*
  Region                                                     
  Northern                       530      152126.20   3.48   1.00
  Central                        224      55922.83    4.01   1.14 (0.98-1.33)
  Southern                       294      71482.77    4.11   1.18 (1.02-1.36)\*
  Eastern                        22       5939.71     3.70   1.06 (0.69-1.63)
  Urbanization                                               
  Urban                          583      164425.75   3.55   1.00
  Suburban                       362      92145.41    3.93   1.11 (0.97-1.26)
  Rural                          125      28900.35    4.33   1.23 (1.01-1.49)\*
  CCI                                                        
  0                              285      117425.26   2.43   1.00
  1                              272      68558.74    3.97   1.59 (1.35-1.88)\*\*
  ≥2                             513      99487.52    5.16   2.04 (1.76-2.36)\*\*
  Group1                                                     
  Inso-NonHyp                    392      119187.82   3.29   1.00
  Inso-Hyp                       133      28097.40    4.73   1.47 (1.21-1.79)\*\*
  Group2                                                     
  NonInso-NonHyp                 410      113218.87   3.62   1.00
  NonInso-Hyp                    135      24967.32    5.41   1.65 (1.36-2.01)\*\*

Incidence, incidence density (1000 per person-years). \*: *p* \< .05. \*\*: *p* \< .001. CHR, crude hazard ratio; CCI, Charlson comorbidity index; CI, confidence interval; PY, person years.

###### 

Adjusted hazard ratios for cancer in the Inso-Hyp and NonInso-Hyp groups according to the type, half-life, and doses of sedative-hypnotics drugs

  Variable                                     Cancer                                              
  ------------------------------------ ------- -------- ----------- ------- ---------------------- ----------------------
  **Inso-Hyp vs. Inso-NonHyp**                                                                     
  Type^a^                                                                                          
  NonHyp                               17064   392      119187.92   3.29    1.00                   1.00
  NonBZD                               354     8        2305.16     3.47    1.08 (0.54-2.18)       1.11 (0.55-2.24)
  BZD                                  840     22       5825.99     3.78    1.15 (0.75-1.77)       1.02 (0.67-1.57)
  Half-life^b^                                                                                     
  NonHyp                               17064   392      119187.92   3.29    1.00                   1.00
  Short-acting                         483     12       3158.77     3.80    1.18 (0.67-2.10)       1.22 (0.68-2.16)
  Intermediate-acting                  1232    33       8074.47     4.09    1.27 (0.89-1.81)       1.16 (0.81-1.65)
  Long-acting                          2551    88       16864.17    5.22    1.62 (1.28-2.04)\*\*   1.73 (1.37-2.19)\*\*
  Dose^c^                                                                                          
  NonHyp                               17064   392      119187.92   3.29    1.00                   1.00
  Low                                  138     5        621.57      8.04    3.13(1.29-7.56)\*      2.70(1.12-6.54)\*
  Medium                               474     15       2130.92     7.04    2.75(1.64-4.61)\*\*    2.07(1.23-3.49)\*
  High                                 5485    157      25001.66    6.28    2.43(2.01-2.94)\*\*    2.46(2.02-3.00)\*\*
  **NonInso-Hyp vs. NonInso-NonHyp**                                                               
  Type^d^                                                                                          
  NonHyp                               17804   410      113218.87   3.62    1.00                   1.00
  NonBZD                               278     9        1462.55     6.15    1.97 (1.01-3.81)\*     1.93 (1.00-3.75)
  BZD                                  2492    70       13899.56    5.04    1.56 (1.21-2.01)\*\*   1.51 (1.17-1.95)\*
  Half-life^e^                                                                                     
  NonHyp                               17804   410      113218.87   3.62    1.00                   1.00
  Short-acting                         592     18       3114.44     5.78    1.83 (1.14-2.94)\*     1.75 (1.09-2.82)\*
  Intermediate-acting                  1481    44       8075.53     5.45    1.70 (1.24-2.32)\*\*   1.65 (1.21-2.26)\*
  Long-acting                          2378    73       13780.34    5.30    1.59 (1.24-2.04)\*\*   1.69 (1.31-2.17)\*\*
  Dose^c^                                                                                          
  NonHyp                               17804   410      113218.87   3.62    1.00                   1.00
  Low                                  957     56       3555.39     15.75   6.79(5.11-9.02)\*\*    5.47(4.10-7.30)\*\*
  Medium                               1764    60       6157.22     9.74    4.57(3.46-6.03)\*\*    3.77(2.85-5.00)\*\*
  High                                 5393    168      20844.67    8.06    3.32(2.75-4.00)\*\*    3.42(2.82-4.14)\*\*

^a^Overall, 3,072 patients prescribed BZDs and nonBZDs were excluded. ^b^In total, 3,227 patients (75.64%) switched from short-acting to intermediate-acting (N=920) or long-acting (N=2307) sedative-hypnotic drugs, and 198 patients (4.64%) switched from intermediate-acting to long-acting sedative-hypnotic drugs. ^c^Low, year mean defined daily dose (DDD) of 7 to 30 during follow-up period; Medium, year mean DDD of 31 to 90 in during follow-up period; High, mean DDD of at least 91 during follow-up period. ^d^Overall, 1,681 patients prescribed BZDs and nonBZDs were excluded. ^e^In total, 2,027 patients (45.54%) switched from short-acting to intermediate-acting (N=672) or long-acting (N=1355) sedative-hypnotic drugs, and 571 patients (12.83%) switched from intermediate-acting to long-acting sedative-hypnotic drugs. \**p* \< 0.05. \*\**p* \< 0.001. AHR, adjusted hazard ratio (adjusted for patient age, sex, income, residential region, urbanization, and Charlson comorbidity index); BZD, benzodiazepine; CI, confidence interval.

###### 

Incidence and AHR for cancer in patients in the Inso-Hyp, Inso-NonHyp, NonInso-Hyp, and NonInso-NonHyp groups

  Cancer (n, %)      Inso-Hyp vs. Inso-NonHyp      NonInso-Hyp vs. NonInso-NonHyp   Inso-Hyp vs. NonInso-Hyp      Inso-NonHyp vs. NonInso-NonHyp
  ------------------ ----------------------------- -------------------------------- ----------------------------- --------------------------------
  All                133 (3.12%) vs. 392 (2.30%)   135 (3.03%) vs. 410 (2.30%)      133 (3.12%) vs. 135 (3.03%)   392 (2.30%) vs. 410 (2.30%)
  Incidence          4.73 vs. 3.29                 5.41 vs. 3.62                    4.73 vs. 5.41                 3.29 vs. 3.62
  AHR (95% CI)       1.49 (1.22-1.82)\*\*          1.68 (1.38-2.05)\*\*             1.04 (0.82-1.33)              1.08 (0.94-1.25)
  Oral cancer        16 (0.38%) vs. 27 (0.16%)     12 (0.27%) vs. 30 (0.17%)        16 (0.38%) vs. 12 (0.27%)     27 (0.16%) vs. 30 (0.17%)
  Incidence          0.56 vs. 0.22                 0.47 vs. 0.26                    0.56 vs. 0.47                 0.22 vs. 0.26
  AHR (95% CI)       2.44 (1.31-4.54)\*            1.92 (0.97-3.81)                 1.25 (0.58-2.68)              0.93 (0.55-1.59)
  Stomach cancer     8 (0.19%) vs. 21 (0.12%)      4 (0.09%) vs. 19 (0.11%)         8 (0.19%) vs. 4 (0.09%)       21 (0.12%) vs. 19 (0.11%)
  Incidence          0.28 vs. 0.17                 0.16 vs. 0.17                    0.28 vs. 0.16                 0.17 vs. 0.17
  AHR (95% CI)       1.60 (0.71-3.63)              1.32 (0.44-4.02)                 2.32 (0.69-7.75)              1.52 (0.81-2.87)
  Colon cancer       22 (0.52%) vs 72 (0.42%)      19 (0.43%) vs. 75 (0.42%)        22 (0.52%) vs. 19 (0.43%)     72 (0.42%) vs. 75 (0.42%)
  Incidence          0.77 vs. 0.60                 0.75 vs. 0.66                    0.77 vs. 0.75                 0.60 vs. 0.66
  AHR (95% CI)       1.35 (0.83-2.17)              1.25 (0.75-2.09)                 1.33 (0.71-2.49)              1.13 (0.81-1.57)
  Liver cancer       16 (0.38%) vs. 42 (0.25%)     22 (0.49%) vs. 40 (0.22%)        16 (0.38%) vs. 22 (0.49%)     42 (0.25%) vs. 40 (0.22%)
  Incidence          0.56 vs. 0.35                 0.87 vs. 0.35                    0.56 vs. 0.87                 0.35 vs. 0.35
  AHR (95% CI)       1.54 (0.86-2.74)              2.53 (1.48-4.32)\*\*             0.84 (0.44-1.62)              1.21 (0.78-1.88)
  Lung cancer        10 (0.23%) vs. 53 (0.31%)     17 (0.38%) vs. 51 (0.29%)        10 (0.23%) vs. 17 (0.38%)     53 (0.31%) vs. 51 (0.29%)
  Incidence          0.35 vs. 0.44                 0.67 vs. 0.45                    0.35 vs. 0.67                 0.44 vs. 0.45
  AHR (95% CI)       0.83 (0.42-1.63)              1.71 (0.98-3.00)                 0.65 (0.29-1.43)              1.37 (0.93-2.03)
  Skin cancer        4 (0.09%) vs. 9 (0.05%)       \_                               \_                            9 (0.05%) vs. 8 (0.04%)
  Incidence          0.14 vs. 0.07                 \_                               \_                            0.07 vs. 0.07
  AHR (95% CI)       1.94 (0.59-6.41)              \_                               \_                            1.42 (0.54-3.75)
  Breast cancer^a^   21 (1.02%) vs. 33 (0.40%)     11 (0.61%) vs. 26 (0.36%)        21 (1.02%) vs. 11 (0.61%)     33 (0.40%) vs. 26 (0.36%)
  Incidence          1.53 vs. 0.57                 1.06 vs. 0.56                    1.56 vs. 1.06                 0.57 vs. 0.56
  AHR (95% CI)       2.85 (1.64-4.96)\*\*          2.08 (1.01-4.28)\*               1.67 (0.80-3.48)              0.97 (0.54-1.64)
  Corpus cancer      \_                            \_                               \_                            9 (0.05%) vs. 6 (0.03%)
  Incidence          \_                            \_                               \_                            0.07 vs. 0.05
  AHR (95% CI)       \_                            \_                               \_                            1.04 (0.36-3.00)
  Prostate cancer    4 (0.09%) vs. 26 (0.15%)      5 (0.11%) vs. 21 (0.12%)         4 (0.09%) vs. 5 (0.11%)       26 (0.15%) vs. 21 (0.12%)
  Incidence          0.14 vs. 0.22                 0.20 vs. 0.18                    0.14 vs. 0.20                 0.22 vs. 0.18
  AHR (95% CI)       0.70 (0.24-2.01)              1.55 (0.57-4.23)                 0.94 (0.24-3.71)              1.70 (0.94-3.05)

Incidence, incidence density (1000 per person-years); AHR: adjusted hazard ratio using Cox proportional hazards regression model after controlling for age, sex, income, region, area, and CCI; \*: *p* \< .05; \*\*: *p* \< .001; ICD-O-3 codes: Oral cancer: C00-C06, C09-C10, C12-C14; Stomach cancer: C16; Colon cancer: C18-C21; Liver cancer: C22; Lung cancer: C33-C34; Skin cancer: C44; Breast cancer: C50; Corpus cancer: C54; Prostate cancer: C61. \_: not applicable because of the sample size; ^a^: only data of female patients were analyzed.
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